Viz
Viz.ai provides an enterprise AI-powered care coordination platform with 50+ FDA-cleared medical imaging algorithms deployed across 2,000 U.S. hospitals. It serves hospitals, health systems, and life sciences companies with multimodal AI spanning neuro, vascular, cardio, pulmonary, and trauma workflows.
- Company typePrivate
- Founded2016
- HeadquartersSan Francisco, United States
- Headcount251–500
- GTM typeB2B
- OfferingSoftware
What Viz does
Viz.ai, Inc. is a San Francisco-based, privately held healthcare AI company founded in 2016 that builds an enterprise AI-powered care coordination platform deployed across 2,000 U.S. hospitals covering approximately two-thirds of the U.S. population. The platform, branded Viz.ai One, integrates more than 50 FDA-cleared AI algorithms across neurological (Viz LVO, ICH, Aneurysm, SDH, CTP), vascular (PE, aortic disease), cardiac (HCM, ACS, cardiac amyloidosis), pulmonary (COPD, lung nodules, PE), radiology, and trauma workflows, with multimodal capabilities spanning imaging AI, ambient listening, NLP, and EHR-integrated generative AI through Viz Assist and Viz Agent Studio. The platform operates PACS-independently and integrates with Epic and eClinicalWorks via HL7 FHIR, enabling cross-hospital communication and specialist notification that isolated PACS-based algorithms cannot replicate.
The company monetizes primarily through quote-based enterprise SaaS subscriptions sold to hospitals, integrated delivery networks, and academic medical centers on multi-year contracts, and through a growing life sciences business involving strategic collaborations with 11 biopharma and medtech companies (Bristol Myers Squibb, Novartis, Sanofi, Regeneron, Alnylam, Johnson & Johnson) for AI-powered care pathway development, clinical trial enrollment, and real-world evidence generation. Distribution combines direct enterprise sales with channel partnerships — notably co-marketing with Johnson & Johnson, integration with Salesforce Agentforce for Health and Microsoft Cloud for Healthcare, and a European joint go-to-market with Medtronic. Viz.ai reached profitability in its healthcare segment in 2025 while doubling its life sciences business, and operates from wholly owned subsidiaries in the U.S. (HQ), the Netherlands, the United Kingdom, and Israel (engineering), holding SOC 2 Type 2, ISO 27001, ISO 27701, and ISO/IEC 42001 certifications alongside HIPAA, GDPR, and CCPA compliance.
Viz firmographics
Firmographics- Name
- Viz
- Legal name
- Viz.ai, Inc.
- Website
- https://viz.ai
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Viz.ai provides an enterprise AI-powered care coordination platform with 50+ FDA-cleared medical imaging algorithms deployed across 2,000 U.S. hospitals. It serves hospitals, health systems, and life sciences companies with multimodal AI spanning neuro, vascular, cardio, pulmonary, and trauma workflows.
- Ownership category
- akta.pro rank
Viz industry classification
Industry- Product category
- Healthcare AI Care Coordination Software
- NAICS
- Computer Systems Design Services (541512)
- SIC
- Services-Computer Integrated Systems Design (7373)
- akta.pro primary industry
- AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)
- akta.pro secondary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
Keywords
Where Viz is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Viz business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Healthcare Subscription (Viz.ai One platform): Recurring SaaS subscriptions from hospitals and health systems for the Viz.ai One platform including Viz Neuro Suite, Viz Cardio Suite, Viz Vascular Suite, Viz Trauma Suite, Viz Radiology Suite, Viz Pulmonary Suite, Viz Assist, and Viz Agent Studio. Deployed in 2,000 U.S. hospitals. Achieved profitability in healthcare segment in 2025.
- Life Sciences Partnerships: Strategic collaborations with 11 biopharma and medtech companies (Bristol Myers Squibb, Novartis, Sanofi, Regeneron, Alnylam, etc.) for AI-powered care pathway development, clinical trial optimization, and real-world evidence generation. Life sciences business doubled in 2025 with six new partnerships.
- Strategic Commercialization Co-Marketing: Commercialization collaborations with medtech companies (e.g., Johnson & Johnson) to co-market AI solutions alongside their therapeutic products, generating revenue through joint go-to-market activities.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Quote-based enterprise subscription for hospitals and health systems |
Go-to-market motion4 records
Distribution channels6 records
Marketing channels10 records
Viz product offering
Product offeringCore offering
Viz.ai operates an enterprise AI-powered care coordination platform (Viz.ai One) that integrates more than 50 FDA-cleared AI algorithms to analyze medical imaging (CT, CTA, MRI, ECG, echocardiogram) and structured clinical data, detect time-critical conditions such as stroke, hemorrhage, pulmonary embolism, aortic disease, and hypertrophic cardiomyopathy, and automatically notify specialists and coordinate care teams across hospital systems. The platform layers in Viz Assist (ambient listening and generative AI workflow assistant), Viz Agent Studio (an enterprise AI agent development platform), and disease-specific suites (Neuro, Vascular, Cardio, Pulmonary, Radiology, Trauma, Oncology) to support care coordination, clinical documentation, and custom AI pathway development.
Product overview
Viz.ai operates as a platform-plus-modules architecture: Viz.ai One is the unifying enterprise AI platform that connects imaging, EHR, and care coordination workflows across the health system, while Viz Assist (an ambient, generative-AI workflow assistant) and Viz Agent Studio (an enterprise agent-building platform) sit on top as cross-cutting AI layers. Beneath the platform, Viz.ai organizes its clinical algorithms into specialty suites — Viz Neuro Suite (including Viz LVO, Viz ICH, Viz CTP, Viz Aneurysm / Viz ANX, Viz SDH, and Viz RV/LV), Viz Vascular Suite (including Viz PE & AD / CINA CHEST), Viz Cardio Suite (including Viz HCM), Viz Pulmonary Suite, Viz Radiology Suite, Viz Trauma Suite, and Viz Oncology Suite — each providing FDA-cleared disease detection and triage modules. Viz.ai Life Sciences extends the same core infrastructure into pharmaceutical and clinical research. The suites integrate with EHR systems (Epic, eClinicalWorks) via FHIR and partner ecosystems including Microsoft Cloud for Healthcare and Salesforce Agentforce for Health.
Differentiator
Problem solved
Functional benefit
Brands
- Viz.ai One: Enterprise AI-powered care coordination platform unifying detection, workflow, and operational impact across therapeutic areas.
- Viz Assist
- Viz Neuro Suite
- Viz Cardio Suite
- Viz Vascular Suite
- Viz Pulmonary Suite
- Viz Radiology Suite
- Viz Trauma Suite
- Viz Oncology Suite
- Viz Life Sciences
- Viz Agent Studio
Products and services
- Viz.ai One
- Viz Assist
- Viz Agent Studio
- Viz Neuro Suite
- Viz Vascular Suite
- Viz Cardio Suite
- Viz Pulmonary Suite
- Viz Radiology Suite
- Viz Trauma Suite
- Viz Oncology Suite
- Viz.ai Life Sciences
Quantifiable outcome
- Reduced interfacility stroke transfer DIDO time by 44% (from 202 to 113 minutes), exceeding Joint Commission's 120-minute national benchmark by nearly 6%.
- +10 more outcomes
Companies that use Viz
Customer profileNamed customers10 records
Segments4 records
Ideal customer profiles3 records
Viz technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration9 records
AI capability14 records
Feature13 records
Viz partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core, flagship and minor.
- National Rural Health Association (NRHA)coreCollaboration through NRHA's Rural Hospital & Clinic Partnership Program to help rural hospitals implement Viz.ai's AI-powered detection and care coordination tools. Includes educational webinars, case studies from peer hospitals, and engagement at NRHA's national conference. Addresses the 25% gap in rural hospital AI adoption. Viz.ai is currently deployed in 2,000 hospitals nationwide with stroke, PE, and aortic disease detection capabilities.
- Johnson & JohnsonflagshipStrategic commercialization collaboration announced April 23, 2026, to expand access to Viz.ai's FDA 510(k)-cleared AI-powered Subdural Hemorrhage software solution across U.S. hospitals. The solution provides automated detection, labeling, and quantification of subdural collections, integrated with Viz Assist for AI-driven chart summarization. The collaboration aims to identify chronic subdural hematoma patients earlier and coordinate multidisciplinary care, including identifying candidates for middle meningeal artery embolization (MMA) treatment, and is expected to drive uptake of J&J's FDA-approved TRUFILL n-BCA Liquid Embolic System.
- Alnylam PharmaceuticalsflagshipStrategic collaboration to develop an AI-enabled care pathway for earlier detection and improved care coordination of cardiac amyloidosis (ATTR-CM). The Viz Cardiac Amyloidosis Care Pathway combines Viz.ai's FDA-cleared Us2.ai echocardiography AI algorithm with generative AI and EHR connectivity, launching with a multi-site pilot study at five pilot U.S. health systems. Viz.ai's Alnylam partnership also supports the AWARE implementation study.
- SalesforceflagshipPartnership to expand Salesforce's Agentforce for Health platform with six new AI agents powered by Viz.ai, automating administrative and clinical workflows across healthcare organizations including patient referrals, electronic health record updates, hospital logistics management, and infectious disease monitoring. Early adopter MIMIT Health reported 459% ROI and $1.5M in savings. Some tools (referral triage, root cause analysis) rolling out in June 2026. Separately, Viz.ai and Salesforce also partnered to transform pharma engagement with real-time clinical intelligence for Agentforce (January 2026).
- Bristol Myers SquibbcoreMulti-year collaboration to develop AI-powered care pathway solutions including Viz HCM for hypertrophic cardiomyopathy detection. Real-world deployment of Viz HCM under the partnership has identified at least 11 new HCM diagnoses, with 63 previously undiagnosed HCM cases detected over eight months, reducing average diagnosis time from years to 37 days.
- NovartiscoreOne of 11 biopharma and medtech companies partnering with Viz.ai to develop AI-powered care pathway solutions. Part of Viz.ai's life sciences business which doubled in 2025 with six new partnerships.
- SanoficoreBiopharma partner collaborating with Viz.ai on AI-powered care pathway solutions across conditions ranging from oncology to cardiovascular diseases. Referenced as a life sciences partner in Viz.ai's blog on bridging AI-powered HCP solutions.
- RegeneroncoreBiopharma partner of Viz.ai developing AI-powered care pathway solutions. Referenced in Viz.ai's article on lung disease management as an example of AI partnerships expanding chronic lung disease care.
- IMVARIAminorReferenced as an example of a Viz.ai AI partnership expanding chronic lung disease care, alongside Sanofi and Regeneron.
- MicrosoftcoreViz.ai integrates with Microsoft Cloud for Healthcare, enabling health systems to access Viz.ai's AI algorithms within the Microsoft Cloud for Healthcare environment. The partnership supports the joint offering "Viz.ai and Microsoft Cloud for Healthcare."
- MedtroniccoreViz.ai Netherlands BV and Viz.ai Group have partnered with Medtronic International Trading Sarl (Medtronic Europe) to undertake joint sales, marketing, and business development activities in Europe. Each organization has separate privacy policies.
- Us2.aicoreViz.ai's FDA-cleared Us2.ai echocardiography AI algorithm is integrated into the Viz Cardiac Amyloidosis Care Pathway. Us2.ai's algorithm analyzes echocardiograms and, combined with generative AI and EHR connectivity, supports earlier identification of cardiac amyloidosis patients and guides clinicians through guideline-based diagnostic steps.
Scale indicators11 records
Recent moves7 records
Expansion highlights8 records
Viz competitors and assessment
Company assessmentMarket position
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Viz social profiles
Digital presenceViz compliance and trust
Trust signalCompliance9 records
Viz financial estimates
Financial estimateRevenue estimate
Valuation estimate
Viz leadership team
Management profileNumber of profiles
Profiles5 records
Viz subsidiaries and ownership
Company hierarchySubsidiaries3 records
Viz funding detail
Funding detailFunding overview
Funding rounds9 records
Investors19 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Viz M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Viz
What does Viz do?
Viz.ai operates an enterprise AI-powered care coordination platform (Viz.ai One) that integrates more than 50 FDA-cleared AI algorithms to analyze medical imaging (CT, CTA, MRI, ECG, echocardiogram) and structured clinical data, detect time-critical conditions such as stroke, hemorrhage, pulmonary embolism, aortic disease, and hypertrophic cardiomyopathy, and automatically notify specialists and coordinate care teams across hospital systems. The platform layers in Viz Assist (ambient listening and generative AI workflow assistant), Viz Agent Studio (an enterprise AI agent development platform), and disease-specific suites (Neuro, Vascular, Cardio, Pulmonary, Radiology, Trauma, Oncology) to support care coordination, clinical documentation, and custom AI pathway development.
Is Viz a public or private company?
Viz is a private company. It is classified as venture growth investor backed and is currently operating.
When was Viz founded?
Viz was founded in 2016. It employs 251 to 500 people.
Where is Viz based?
Viz is headquartered in San Francisco, United States, in the North America region.
How does Viz make money?
Three revenue lines are on record. Healthcare Subscription (Viz.ai One platform) is the primary driver. The others are life Sciences Partnerships and strategic Commercialization Co-Marketing.
Does Viz have an API?
Yes. FHIR-based EHR integration enables bidirectional data exchange with electronic health record systems, allowing Viz.ai to ingest clinical data and write AI-generated insights back to the patient record. Integrations leverage standards-based FHIR APIs to surface imaging, labs, and clinical context within the care coordination workflow. No standalone public developer API portal was identified.
What industry is Viz in?
Viz's product category is Healthcare AI Care Coordination Software. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage), with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 541512 and its SIC code is 7373.